| |
 |
|
RENAL DATA FROM THE ARAB WORLD |
|
|
|
| Year : 2014 | Volume
: 25
| Issue : 3 | Page : 672-679 |
|
| Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: Prevalence and risk factors |
|
|
Zineb Lioussfi, Zineb Errami, Aicha Radoui, Hakima Rhou, Fatima Ezzaitouni, Naima Ouzeddoun, Rabea Bayahia, Loubna Benamar
Department of Nephrology, Dialysis and Renal Transplantation, Ibn Sina Hospital, Rabat, Morocco
Click here for correspondence address and email
| Date of Web Publication | 9-May-2014 |
|
|
 |
|
 Abstract | | |
The aim of this study is to investigate the prevalence of hepatitis C virus (HCV) and hepatitis B virus (HBV) in maintenance hemodialysis (HD) and continuous ambulatory peritoneal dialysis patients at the Rabat University Hospital and to identify the major risk factors for transmission. A retrospective study was performed in 67 chronic HD and 36 peritoneal dialysis patients. For the screening of viral infections, we tested for anti-HCV antibodies and HBs antigen (Hbs Ag). We compared infected and non-infected patients in order to determine the risk factors for contamination. In the HD unit, the prevalence of anti-HCV was 60% and the prevalence of HBs Ag was 6%. Duration of dialysis (P = 0.001) was the only risk factor in our HD patients. In peritoneal dialysis (PD), the prevalence of anti-HCV was 8%. Hbs Ag was detected in 2.6% of our PD patients. Viral hepatitis C is the main viral infection in our HD unit. The duration of dialysis is the main risk factor for infection in our study. The transmission is essentially nosocomial, requiring a strict adherence to infection control procedures.
How to cite this article:
Lioussfi Z, Errami Z, Radoui A, Rhou H, Ezzaitouni F, Ouzeddoun N, Bayahia R, Benamar L. Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: Prevalence and risk factors. Saudi J Kidney Dis Transpl 2014;25:672-9 |
How to cite this URL:
Lioussfi Z, Errami Z, Radoui A, Rhou H, Ezzaitouni F, Ouzeddoun N, Bayahia R, Benamar L. Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: Prevalence and risk factors. Saudi J Kidney Dis Transpl [serial online] 2014 [cited 2023 Feb 4];25:672-9. Available from: https://www.sjkdt.org/text.asp?2014/25/3/672/132236 |
| Introduction | |  |
Patients in end-stage renal disease (ESRD) undergoing chronic dialysis are at a high risk of exposure to hepatitis C virus (HCV) and hepatitis B virus (HBV). The main viral infection among patients on chronic hemodialysis (CHD) remains viral hepatitis C, which represents a major health issue, first with a high prevalence and then with a progressive risk to chronicity, developing either cirrhosis or hepatocellular carcinoma. In addition, there is the risk of cross-contaminations in dialysis units.
Several ways of transmission have been reported by studies, but the efficiency of hygienic measures in some dialysis units, [1] the low prevalence in peritoneal dialysis compared with hemodialysis (HD) [2] and the new cases of contamination in non-toxico-maniac nor transfused patients suggest a hand-borne nosocomial transmission. [3],[4] Prevention from viral infections in patients on chronic dialysis mainly rests on the strict adherence of hygienic and universal precautions.
The aim of this study is to determine the prevalence of anti-HCV antibody and HbsAg in ESRD patients undergoing either HD or peritoneal dialysis (PD) at the Rabat University Hospital and to specify the major risk factors of contamination in this population.
| Materials and Methods | | |
Patients
A transverse study was carried out during July 2009 in the dialysis unit, including all the ESRD patients, undergoing either HD or PD.
From our HD population in July 2009, 67 patients were enrolled in the study, with a sex ratio of 0.8 (31 male/36 female) and a mean age of 44.2 ± 12 years (25-88 years). The mean duration of HD was 10.6 ± 5.2 years (3-20 years). The native kidney disease could be determined in 61.2%, mostly chronic glomerulonephritis (19.4%) and diabetic nephropathy (10.4%). Our patients had between two and three dialysis sessions per week, lasting 4-5 h, with polysulfone membranes. Our unit is composed of 12 dialysis machines, there is a nurse for every six patients and every adjacent patient is separated by a meter.
From the PD population in July 2009, 38 patients were enrolled, all on continuous ambulatory peritoneal dialysis (CAPD). The mean age was 46 years ± 19 (10-80 years), with a male superiority (24 male/14 female). The mean duration of dialysis was 16.2 ± 9.27 months (3-36 months). The initial kidney disease was known in 60%, and was mostly chronic glomerulonephritis (13%) and diabetic nephropathy (21%). Ten patients (26%) resorted to HD before starting PD.
Methods
Screening of viral infections
HCV antibody test was performed according to the KDOQI guidelines [5] and European best practice guidelines (EBGP) [6] before starting dialysis at the unit and every six months following that using a fourth-generation enzyme-linked immunosorbent assay (ELISA) test. In HCV antibody carriers, the confirmation was performed by quantitative polymerase chain reaction (PCR) (Test AmpliPrep/Cobas TaqMan HCV-Roche Diagnostics Basel, Switzerland) with, a detection threshold of 15 IU/mL. Genotype testing was performed only in a few cases.
We systematically tested for HbsAg, anti-Hbc and anti-Hbs antibodies by the ELISA technique in all our patients. For some patients, the confirmation was done by the real-time PCR method
Risk factors for contamination
We studied risk factors for contamination among all the patients: Duration of dialysis, number of blood transfusions, quantity of red blood cells transfused, dental care needs and history of surgery including renal transplant. In order to evaluate risk factors, we compared two groups of patients according to their serological status, in each dialysis group: group I consisting of the infected patients and group II the non-infected ones.
| Results | | |
In hemodialysis patients
HCV prevalence
In July 2009, among 67 patients on CHD, anti-HCV antibody was positive in 40 patients, a prevalence rate of 60%. PCR was positive for 28 patients, with a prevalence of 42%, and the mean viral charge of HCV RNA was 724 693 ± 1441717 IU/mL. The genotype was performed in 12 among 28 infected patients, and we noticed genotype 1b in all these patients.
One patient was positive for anti-HCV antibody before starting the dialysis sessions in our unit. The mean period for seroconversion of HCV markers after the beginning of HD is 4.4 ± 3.4 years (1-13 years). After a mean period of 7.8 ± 5.7 years (1-19 years) from seroconversion, no infected patient showed symptoms for cirrhosis or hepatocarcinoma.
HCV infection risk factors
In univariate analysis, the HCV exposure risk is related to duration of dialysis and to surgical history [Table 1]. Main surgical procedures are parathyroidectomies, traumatology surgeries and renal transplantations.
In a multivariate study, duration of dialysis remains the only risk factor related to the high prevalence [Table 2]. Indeed, the prevalence of HCV infection increases from 36% during the five first dialysis years to 82% in the latest ten years and 98% in the latest 15 years [Figure 1].
HBV
Among our 67 CHD patients, four was tested positive for Hbs Ag, resulting in a prevalence of 6%. Two patients were already infected before their admission in the unit. The two remaining patients got infected in the first year after starting dialysis. We noticed a co-infection with HCV in two cases. Thirty-five patients (52%) had exposure to HBV previously and were immunized, carrying anti-Hbc and anti-Hbs antibodies. The rest of the patients having negative anti-Hbc and anti-Hbs received a hepatitis B vaccination. Recombinant HBV vaccine 40 IU was administered by the subcutaneous route according to a 0-, 1- and 2-month schedule, with an anti-Hbs anti-body titration three months after the last injection. Only 28 patients (16%) were protected, with an anti-Hbs antibody rate over 100 IU/ mL and a mean of 347 ± 401 IU/mL.
In PD patients
HCV prevalence
From a total of 38 patients, anti-HCV antibody screening was positive in three cases, corresponding to a seroprevalence of 8%. We did not notice any HCV seroconversion in the uninfected population after a mean dialysis duration of 16.2 ± 9.27 months. Among the three patients, only one was in HD before changing for PD. PCR was negative in one patient and the mean viral charge in the two remaining patients was 7 095 512 ± 855698 IU/mL. A hepatic biopsy was performed in the two cases anti-HCV antibody (+) PCR (+) and showed a chronic hepatitis with a minimal activity and a moderate portal fibrosis (A1F2).
HBV prevalence
The Hbs Ag detection was positive in one patient, meaning a HBV prevalence of 2.6%, with a positive PCR. The hepatic biopsy showed signs of chronic hepatitis with no activity or fibrosis (A0F0). After a mean duration of 16.2 ± 9.27 months (3-36 months), no new HBV case appeared in our unit. None of the other patients had positive anti-Hbc.
| Discussion | | |
Hepatitis C is the main viral infection among HD patients. Its prevalence in this population at risk has been studied since the 1990s, and is different from country to country and between HD units. The prevalence is estimated to be around 13%, with values fluctuating between 3% and 23% according to a prospective study: Dialysis Outcomes and Practice Patterns Study (DOPPS). [7] [Table 3] summarizes the results of some publications about the prevalence of HCV in HD patients across the five continents.
The prevalence in our HD patients was 60%, which is a higher rate compared with the literature. It is even higher than the prevalence seen in the general population of Morocco (1.93%) [16] and the blood donors (1.08%). [17]
The prevalence of HCV in our PD center is low (8%). In other studies, this prevalence fluctuates between 5% [18] and 30%, [19] depending on PD centers, geographic areas and HD history. It is estimated at 312% in France, [20] 5.7% in Germany, [18] 5.3% in Korea, [21] 2.2% in Hong Kong, [22] and 30% in China. [19]
The history of HD is a major risk factor of HCV contamination in the CHD population. The mean period of dialysis among HCV (+) patients on CHD varies between 2.75 [23] and 8.6 years. [15] In a multi-center study performed in south France, Dussol concluded that an over eight-year period constitutes the main risk factor for HCV infection. [24] In our series, we found a period of 10.6 ± 5.17 years as the unique risk factor in multivariate analysis [Table 4].
Blood transfusion and quantity of red blood cells transfused were considered as contamination risk factors for HCV in CHD. [30] However, erythropoietin use for treating ESRD anemia and a systematic screening for certain infections including viral hepatitis on blood donors since 1994 led to a significant reduction in the risk of post-transfusion infection. [31] The genomic screening innovation [32] in some countries such as France since 2001 has reduced this risk. Moreover, 20% of the HCV (+) patients of our study population have never been transfused, and 90% were contaminated after 1994, the starting year for systematic control of blood donations and the screening for viral hepatitis in Morocco.
In PD, the risk of contamination by HCV is reduced and, unlike HD, the duration of dialysis does not constitute a risk factor for this population. [2] Studies comparing prevalence in PD and HD showed low rates of anti-HCV (+) in PD [Figure 2]. The main risk factor in PD is the medical history of HD before starting peritoneal exchanges. Huang found a prevalence of 15.4% of HCV in PD, but after disqualifying patients with an HD history, the prevalence was 5.9%. [37] Several factors might explain this low prevalence in PD, mainly the lack of vascular access or an extra-corporal circulation and the homemade technique that reduces the nosocomial transmission.
Published data from the DOPPS study [38] showed that the mean prevalence of HBV fluctuates between 0% in the United Kingdom and 6.6% in Italy [Table 5]. The low prevalence observed in UK is explained by the large spread of PD to treat ESRD. [38] In our unit, 6% are Hbs Ag positive, despite the systematic vaccination in chronic dialysis patients. The prevalence is higher compared with the general population in Morocco: 1-3%, [39] and to blood donors: 2.01%. [17]
The management of viral infections in chronic dialysis essentially remains on preventive measures. Indeed, the incidence and prevalence of infections have decreased thanks to screening and prevention progress, but also to adequate hygienic and disinfection practice. [40] However, we still have de novo contaminations in HD units due to difficulties in applying universal hygienic precautions. Moreover, PD and home dialysis do help to prevent from infections. An early renal transplantation reduces the contamination risk.
Systematic and repeated screening of anti-HCV antibodies by the ELISA technique is necessary in each HD patient newly registered in a HD unit or when one gets transferred from another HD unit. [5] In case of positive serology, a second sample is indicated to eliminate an error. Then, a PCR investigation is needed to confirm the presence of viral RNA. The National Kidney Foundation states the situations for serological screening and PCR confirmation. [5]
There is still a debate concerning the separation between infected and uninfected patients, based on the argument of contracting virus by parenteral and nosocomial means of transmission. On the other hand, identifying and isolating contaminators are still difficult, and a negative serological test does not exclude infection due to the six-month possible serological interval. In our HD unit, infected and uninfected patients are not separated.
Nowadays, there is no efficient vaccine against HCV. RNA viruses quickly evolve, and to get a vaccine against many genotypes is a hard task. [41]
Concerning HBV infection, recommendations are for systematic vaccination in ESRD patients at an early stage in order to maximize the vaccine response. Available data show that this vaccination protects a large majority of HD patients, but vaccine-induced antibody levels decline with time. However, immune memory remains intact for more than 20 years following immunization, and both adults and children with declining antibody levels are still protected against significant HBV infection. [42]
HCV is the most common viral infection in patients on chronic dialysis in the Rabat University Hospital, especially in the HD unit. This phenomenon might be related to the long survival on HD and to the difficulties to follow hygienic universal procedures. Preventing infections starts by being rigorous in hygienic measures and also by promoting PD and kidney transplantation.
Conflict of interest: None
| References | | |
| 1. | Jadoul M, Cornu C, Van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: A 54 month follow-up of the Belgian Multicenter Study. Kidney Int 1998;53:1022-5. 
|
| 2. | Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997;51:981-99.
|
| 3. | Leung N, Chu C, Tam JS. Viral hepatitis C in Hong Kong. Intervirology 2006;49:2-7.
|
| 4. | Sampietro M, Badalamenti S, Salvadori S, et al. High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: Evidence for nosocomial transmission of HCV. Kidney Int 1995;47:911-7.
|
| 5. | Gordon CE, Balk EM, Becker BN, et al. KDOQI US Commentary on the KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in CKD. Am J Kidney Dis 2008;52: 811-25.
|
| 6. | European best practice guidelines. Nephrol Dial Transplant 2002;17:78-81.
|
| 7. | Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2004;65:2335-42.
|
| 8. | Bdour S. Hepatitis C virus infection in Jordanian haemodialysis units: Serological diagnosis and genotyping. J Med Microbiol 2002;51:700-4.
|
| 9. | Shaheen FA, Huraib SO, Al-Rashed R, et al. Prevalence of hepatitis C antibodies among hemodialysis patients in Jedda area, Saudi Arabia. Saudi Med J 2003;2:125-6.
|
| 10. | Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: A multicenter study. J Med Virol 2000;61:44-51.
|
| 11. | Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Folsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: A multi-center study in 2796 patients. Gut 2002;51: 429-33.
|
| 12. | Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007;18:1584-93.
|
| 13. | Bouzgarrou N, Fodha I, Othman SB, et al. Evaluation of a total core antigen assay for the diagnosis of hepatitis C virus infection in hemodialysis patients. J Med Virol 2005;77: 502-8.
|
| 14. | Carneiro MA, Martins RM, Teles SA, et al. Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: A survey by polymerase chain reaction and serological methods. Mem Inst Oswaldo Cruz 2001;96:765-9.
|
| 15. | Boulaajaj K, Elomari Y, Elmaliki B, Madkouri B, Zaid D, Benchemsi N. Prevalence of hepatitis C, hepatitis B and HIV infection among haemodialysis patients in Ibn-Rochd university hospital, Casablanca. Néphrol Thér 2005;1:274-84.
|
| 16. | Benouda A, Boujdiya Z, Ahid S, Abouqal R, Adnaoui M. Prevalence of hepatitis C virus infection in Morocco and serological tests assessment of detection for the viremia prediction. Pathol Biol 2009;57:368-72.
|
| 17. | The Regional Blood Transfusion Center of Casablanca (RBTC). Statistics. 2002.
|
| 18. | Gladziwa U, Schlipkoter U, Lorbeer B, Cholmakow K, Roggendorf M, Sieberth HG. Prevalence of antibodies to hepatitis -virus in patients on peritoneal dialysis - a multicenter study. Clin Nephrol 1993;40:46-52.
|
| 19. | Ng YY, Lee SD, Wu SC, Yang WC, Chiang SS, Huang TP. Antibodies to hepatitis C virus in uremic patients on continuous ambulatory peritoneal dialysis. J Med Virol 1991;35:263-6.
|
| 20. | Durand PY, Chanliau J, Gamberoni J, Hestin D, Kessler M. Prevalence and Epidemiology of Hepatitis C Infection in Patients on Peritoneal Dialysis in France. Adv Perit Dial 1996; 12:167-70.
|
| 21. | Nakashima F, Sata M, Tokeshi S, et al. Incidence of antibodies to hepatitis C virus in patients undergoing chronic dialysis and CAPD. KurumeMed J 1993;40:249-53.
|
| 22. | Chan TM, Lok AS, Cheng IK. Hepatitis C infection among dialysis patients: A comparison between patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1991;6:944-7.
|
| 23. | Hachicha J, Hammami A, Masmoudi H, et al. Viral hepatitis C in chronic hemodialyzed patients in southern Tunisia. Prevalence and risk factors. Ann Med Interne (Paris) 1995;146 Suppl 5:295-8.
|
| 24. | Dussol B, Berthezene P, Brunet P, Berland Y. Hepatitis C virus infection among chronic dialysis patients in the south-east of France. Nephrol Dial Transplant 1995;10:477-8.
|
| 25. | Huraib S, Alrashed R, Aldresse A, Aljefry M. High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saoudi Arabia. Nephol Dial Transplant 1995;10:470-4.
|
| 26. | Pol S, Legendre C. Viral hepatitis in hemodialysis and renal transplantation patients. Néphrologie 1994;15:191-5.
|
| 27. | Olivia JA, Maymo RM, Carrio J. Late sero-conversion of C virus markers in hemodialysis patients. Kidney Int 1993;41:153-6.
|
| 28. | Chen KS, Lo SK, Lee N, Lee ML, Huang CC. Superinfection with hepatitis C virus in hemodialysis patients with hepatitis B surface anti-genemia: Its prevalence and clinical significance in Taiwan. Nephron 1996;73:158-64.
|
| 29. | Ben Othman S, Bouzgarrou N, Achour A, Bourlet T, Pozzetto B, Trabelsi A. High prevalence and incidence of hepatitis C virus infections among dialysgis patients in the East- Centre of Tunisia. Pathol Biol (Paris) 2004;52: 323-7.
|
| 30. | Wreghitt TG. Blood-borne virus infections in dialysis units - a review. Rev Med Virol 1999;9:101-9.
|
| 31. | Stramer SL. Current risks of transfusion transmitted agents: A review. Arch Pathol Lab Med 2007;131:702-7.
|
| 32. | Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in hemodialysis patients: Current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol 2008;28:628-40.
|
| 33. | Yoshida C, Takahashi C, Gaspar A, Schatzmayr H, Ruzany F. Hepatitis C virus in chronic hemodialysis patients with non-A, non-B hepatitis. Nephron 1992;60:150-3.
|
| 34. | Selgas R, Martinez-Zapico R, Bajo MA, et al. Prevalence of hepatitis C antibodies (HCV) in a dialysis population at one center. Perit Dial Int 1992;12:28-30.
|
| 35. | Barril G, Traver JA. Prevalence of hepatitis C virus in dialysis patients in Spain. Nephrol Dial Transplant 1995;10 Suppl 6:78-80.
|
| 36. | Mcintyre PG, Mc Cruden EA, Down BC, et al. Hepatitis C virus infection in renal dialysis patients in Glasgow. Nephol Dial Transplant 1994;9:291-5.
|
| 37. | Huang CC, Wu MS, Lin DY, Liaw YF. The prevalence of hepatitis C virus antibodies in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1992;12:12-3.
|
| 38. | Burdick RA1, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2003;63:2222-9.
|
| 39. | Filali Baba A. Diseases in Morocco, a general overview. Medical Events 2002;6:1-2.
|
| 40. | Furusyo N, Hayashi J, Kakuda K, et al. Acute hepatitis C among Japanese hemodialysis patients: A prospective 9-year study. Am J Gastroenterol 2001;96:1592-600.
|
| 41. | Pascal JP. Transmission and prévention of viral hépatitis. Rev Prat 1995;45:174-9.
|
| 42. | Centers for Disease Control and Prevention (CDC). Hepatitis B: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook - 12th Edition Second Printing (May 2012), pages 115-138. Centers for Disease Control and Prevention 1600 Clifton Rd Atlanta, GA 30333.
|
Correspondence Address:
Dr. Zineb Lioussfi
Department of Nephrology, Dialysis and Renal Transplantation, Ibn Sina Hospital, Rabat
Morocco
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1319-2442.132236
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5] |
|
| This article has been cited by | | 1 |
Meta-analysis: Risk of hepatitis C virus infection associated with hospital-based invasive procedures |
|
| Paul Henriot, Mathieu Castry, Liem Binh Luong Nguyen, Yusuke Shimakawa, Kévin Jean, Laura Temime | | Alimentary Pharmacology & Therapeutics. 2022; | | [Pubmed] | [DOI] | | | 2 |
Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Patients Undergoing Maintenance Hemodialysis |
|
| Usama Bin Shabbir, Wajih Ul Hassan, Ali Raza, Sadia Hafiz, Hafsa Ansar | | Cureus. 2022; | | [Pubmed] | [DOI] | | | 3 |
The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis |
|
| Tiruneh Adane, Solomon Getawa, Isabelle Chemin | | PLOS ONE. 2021; 16(6): e0251570 | | [Pubmed] | [DOI] | | | 4 |
Updated Evidence on the Epidemiology of Hepatitis C Virus in Hemodialysis |
|
| Fabrizio Fabrizi, Roberta Cerutti, Piergiorgio Messa | | Pathogens. 2021; 10(9): 1149 | | [Pubmed] | [DOI] | | | 5 |
A Systematic Review of the Current Hepatitis B Viral Infection and Hepatocellular Carcinoma Situation in Mediterranean Countries |
|
| Salma Madihi, Hashim Syed, Fatiha Lazar, Abdelmajid Zyad, Abdelouaheb Benani | | BioMed Research International. 2020; 2020: 1 | | [Pubmed] | [DOI] | | | 6 |
Risk factors associated with nosocomial infections among end stage renal disease patients undergoing hemodialysis: A systematic review |
|
| Saad Hanif Abbasi, Raja Ahsan Aftab, Siew Siang Chua, Laura Pasin | | PLOS ONE. 2020; 15(6): e0234376 | | [Pubmed] | [DOI] | | | 7 |
Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient |
|
| Jin Chen, Yi Li, Guisen Li, Pu Lei | | Renal Failure. 2020; 42(1): 377 | | [Pubmed] | [DOI] | | | 8 |
Hepatitis C and Its Metabolic Complications in Kidney Disease |
|
| Fabrizio Fabrizi, Francesca M. Donato, Piergiorgio Messa | | Annals of Hepatology. 2017; 16(6): 851 | | [Pubmed] | [DOI] | |
|
|
|
|
|
|
|
|
|
|
|
|
| Article Access Statistics | | | Viewed | 4451 | | | Printed | 62 | | | Emailed | 0 | | | PDF Downloaded | 711 | | | Comments | [Add] | | | Cited by others | 8 | | |
|
|
